- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02994147
A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy
July 7, 2020 updated by: TWi Biotechnology, Inc.
Repeated joint bleeding leads to hemophilic arthropathy (HA), which manifests with chronic synovitis, cartilage damage and bony destruction.
Currently available treatments of HA, including analgesics, NSAIDs, and hyaluronic acid, are predominantly directed toward the symptomatic relief of pain and inflammation, with no or little effect on joint cartilage degeneration.
AC201CR, a control released formulation of AC-201, demonstrates anti-inflammatory effects by reducing NLRP3 inflammasome assembly.
AC-201 is also unique in that it influences both the anabolism and catabolism of chondrocytes in vitro and has shown cartilage-sparing properties in animal studies.
The study is designed to evaluate the joint structure-modifying and symptom-relieving effects, safety, and tolerability of AC-201CR in subjects with HA.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan
- Tri-Service General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male age 20 to 65 years, inclusive
- Diagnosis of Hemophilia A or B
- Clinical diagnosis of hemophilic arthropathy in the knee(s) for at least 6 months
- Pettersson score (based on X-ray) of 0 to 4 in at least one knee within 1 year of screening
- IPSG (2012) overall score of 3 to 9 (based on MRI) in at least one knee at screening
- Is able to read, understand, and sign the Informed Consent Form (ICF), communicate with the investigator, complete study diaries, and understand and comply with protocol requirements
Exclusion Criteria:
- Total knee replacement in the primary knee
- Presence of joint infections in the primary knee
- Knee surgery within 6 months prior to screening in the primary knee
- Intra-articular hyaluronic acid (IAHA) or platelet-rich plasma (PRP) injection in the primary knee within 6 months prior to screening
Use of any of the following medications after the screening visit:
- NSAID injection (oral NSAIDs including COX-2 inhibitors allowed)
- Glucosamine or chondroitin
- History of high responder inhibitory antibodies to factor VIII or factor IX clotting factor, with titer >5 Bethesda units (BU), OR clinical evidence for presence of factor inhibitor
- History of rheumatoid arthritis or gouty arthropathy
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentration >2x the upper limit of laboratory normal range (ULN), or bilirubin >1.5x ULN at screening
- Positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or TB
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Placebo-only control study medication is the same formulation as active treatment without active ingredient
|
EXPERIMENTAL: AC-201CR 72mg
|
The investigational product is formulated as controlled-release (CR) tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in IPSG (MRI) score for primary knee
Time Frame: 24 Weeks
|
Knee arthropathy will be evaluated according to the 2012 IPSG (International Prophylaxis Study Group) rating scale.
This scale is an additive scale with maximum value up to 17 points, comprising 2 subscores of soft tissue changes (maximum 9 points) and osteochondral changes (maximum 8 points).
|
24 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in IPSG (MRI) score for non-primary knee
Time Frame: 24 Weeks
|
24 Weeks
|
Change from baseline in IPSG score by knee
Time Frame: 48 Weeks
|
48 Weeks
|
Change from baseline in IPSG component scores by knee
Time Frame: 24 Weeks and 48 Weeks
|
24 Weeks and 48 Weeks
|
Change from baseline in MRI-measured synovial thickness by knee
Time Frame: 24 Weeks and 48 Weeks
|
24 Weeks and 48 Weeks
|
Change from baseline in ultrasonographic synovial thickness by knee
Time Frame: 24 Weeks and 48 Weeks
|
24 Weeks and 48 Weeks
|
Change from baseline in ultrasonographic hyperemia score by knee
Time Frame: 24 Weeks and 48 Weeks
|
24 Weeks and 48 Weeks
|
Change from baseline in knee pain (by VAS) by knee
Time Frame: 4, 12, 24, 28, 36 and 48 Weeks
|
4, 12, 24, 28, 36 and 48 Weeks
|
Change from baseline in Short Form-36 score
Time Frame: 24 Weeks and 48 Weeks
|
24 Weeks and 48 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 21, 2017
Primary Completion (ACTUAL)
April 18, 2019
Study Completion (ACTUAL)
October 2, 2019
Study Registration Dates
First Submitted
December 9, 2016
First Submitted That Met QC Criteria
December 13, 2016
First Posted (ESTIMATE)
December 15, 2016
Study Record Updates
Last Update Posted (ACTUAL)
July 9, 2020
Last Update Submitted That Met QC Criteria
July 7, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC-201CR-HA-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilic Arthropathy
-
Tremeau Pharmceuticals, Inc.TerminatedHemophilic ArthropathyUnited States, Italy, Turkey, Spain, Australia, Canada, Ukraine, Poland
-
Investigación en Hemofilia y FisioterapiaCompleted
-
Tri-Service General HospitalTerminatedHemophilia | Hemophilic ArthropathyTaiwan
-
Cukurova UniversityCompleted
-
Cairo UniversityCompletedHaemophilic Arthropathy of KneeSaudi Arabia
-
Investigación en Hemofilia y FisioterapiaRecruiting
-
Investigación en Hemofilia y FisioterapiaCompleted
-
Real Fundación Victoria EugeniaUnknown
-
Investigación en Hemofilia y FisioterapiaNot yet recruiting
-
Investigación en Hemofilia y FisioterapiaActive, not recruitingHemophilia ArthropathySpain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States